During the COVID-19 pandemic, as an extraordinary measure, within the framework of fast-track recommendation development, based on the recommendation of the Minister of Health of 27 March 2020, the Agency prepared:
“Polish diagnostic, therapeutic and organizational recommendations for the care of individuals infected with SARS-CoV-2 or exposed to a SARS-CoV-2 infection” – version 1.0, 25 April 2020. (PL, EN)
Due to the rapidly changing pandemic situation and the constant influx of new scientific evidence confirming clinical effectiveness and safety of medical technologies applied in COVID-19, the Agency continuously updates the Recommendations.
Collection of updated COVID-19 recommendations:
- COVID-19 pharmacotherapy – updated Recommendations (version 2.8, 13 July, 2021).
- COVID-19 diagnostics – updated Recommendations (version 2.1, 27 May 2021)
As part of the above activities, scientific report reviews (Rapid Reviews) concerning individual drug technologies applied in the case of COVID-19 (systemic corticosteroids, lopinavir administered in combination with ritonavir, remdesivir, tocilizumab, favipiravir, and convalescent plasma, anakinra, interferon beta, amantadine, hydroxychloroquine and chloroquine, anticoagulants, acetylsalicylic acid and clopidogrel, bamlanivimab, ivermectin, regdanvimab, REGN-COV2, sotrovimab, lenzilumab, baricitinib+remdesivir, inhaled corticosteroids, human immunoglobulin, baricitinib, mesenchymal stem cells, antibiotics, sarilumab, tofacitinib, sulodexide) have also been published. Analytical studies constitute the basis for the discussions conducted by the Panel of Clinical Experts.
Training courses on oxygen therapy are available on the website of the Postgraduate Medical Education Center:
- Respiratory failure – oxygen therapy, mechanical ventilation, or V-V ECMO?
- Oxygen toxicity
- High-flow nasal oxygen therapy in the era of COVID-19
More information about the lectures can be found on the website.